I can't say either way if it's finished, but from my viewpoint...

I can't say either way if it's finished, but from my viewpoint it reverts to highly speculative share again, no different to how it was before the pandemic - science amazing, yet to be commercialised. Immediately pre-pandemic the share price was 2c. Ellume royalties will help tick the runs over, but I think we're back to saving money and hoping for the best. This is all my opinion, obviously, but I just think TGA will be too big a struggle to overcome, as are regulatory hurdles in Europe, with increasingly less of a need for what we offer. EuGeni in the Covid world, I believe, will never happen. And now we have to seek approval for a multiplex test that is even more complicated, with less of an urgent public need (at least, less of a perception of that need).
Where do you think the share price will be in a month, two months, three months if there's still no TGA approval? If the company knows it will never happen, it should rip the band aid off and inform the market. In saying that, the chairman is the sort of person who wastes company funds ringing investors before the AGM, asking if he still had his job. That sort of chairman is interested more in their own survival than the public good, so expect more smoke and mirrors and the death of a thousand cuts.